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Abstract
Background: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate
S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed
vancomycin therapy. Up-regulation of genes associated with the "cell wall stimulon" and mutations
in the vraSR operon have both been implicated in the development of resistance, however the
molecular mechanisms of resistance are not completely understood. To further elucidate the
mechanisms leading to resistance transcriptome comparisons were performed using multiple
clinical pairs of vancomycin-susceptible S. aureus (VSSA) and hVISA/VISA (n = 5), and three VSSA
control pairs from hospitalized patients with persistent bacteraemia that did not develop hVISA/
VISA. Based on the transcriptome results multiple genes were sequenced and innate immune
system stimulation was assessed in the VSSA and hVISA/VISA pairs.
Results: Here we show that up-regulation of vraS and the "cell wall stimulon" is not essential for
acquisition of low-level vancomycin resistance and that different transcriptional responses occur,
even between closely related hVISA/VISA strains. DNA sequencing of vraSR, saeSR, mgrA, rot, and
merR regulatory genes and upstream regions did not reveal any differences between VSSA and
hVISA/VISA despite transcriptional changes suggesting mutations in these loci may be linked to
resistance in these strains. Enhanced capsule production and reduced protein A expression in
hVISA/VISA were confirmed by independent bioassays and fully supported the transcriptome data.
None of these changes were observed in the three control pairs that remained vancomycin-
susceptible during persistent bacteremia. In a macrophage model of infection the changes in cell
surface structures in hVISA/VISA strains were associated with significantly reduced NF-κB
activation resulting in reduced TNF-α and IL-1β expression.
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BMC Microbiology 2008, 8:39 http://www.biomedcentral.com/1471-2180/8/39Conclusion: We conclude that there are multiple pathways to low-level vancomycin resistance in
S. aureus, even among closely related clinical strains, and these can result in an attenuated host
immune response. The persistent infections associated with hVISA/VISA strains may be a
consequence of changes in host pathogen interactions in addition to the reduced antibiotic
susceptibility.
Background
Low-level vancomycin resistance in Staphylococcus aureus
(vancomycin-intermediate S. aureus [VISA], and heteroge-
nous-VISA [hVISA]) is associated with vancomycin treat-
ment failure and persistent infection [1-4]. The
mechanisms underlying hVISA/VISA appear to involve
step-wise processes under vancomycin selective pressure
[5,6]. Global metabolic changes affecting the synthesis
and structure of the bacterial cell wall are the major phe-
notypic features. These include cell wall thickening [7-9]
associated with increased production of abnormal
muropeptides [10], increased D-ala-D-ala residues and
reduced peptidoglycan cross-linking [11], reduced growth
rate, and reduced autolytic activity [8,11,12]. The thick-
ened cell wall that results is thought to prevent diffusion
of vancomycin to its active site in the cytoplasmic mem-
brane [13].
The two-component regulatory system vraSR, was shown
to be up-regulated in the Japanese strains Mu50 and Mu3
[14] and the VISA strain JH9 [15]. vraSR is a part of the
"cell wall stimulon" that positively modulates cell wall
biosynthesis, is induced by cell wall active agents [16,17],
and has been suggested to be consistently up-regulated in
VISA strains [15,18]. It is postulated that the cell wall
active glycopeptides stimulate the over expression of the
"cell wall stimulon" and promote resistance by increasing
cell wall thickness. Recently, the complete genome
sequencing of an isolate pair from a single patient demon-
strated a small number of mutations associated with the
VISA phenotype. Early in the evolution of resistance a
mutation in the vraSR operon was detected [6]. Point
mutations and inactivation of agr, an important quorum
sensing global regulatory system in S. aureus, have been
previously described in some VISA strains [19], and were
associated with higher levels of resistance in strain JH9
[6], but are not a consistent finding. Recently, a number of
additional genes were found to be over expressed in VISA
strains and selective over-expression of these genes in the
vancomycin susceptible strain N315 led to subtle
increases in vancomycin resistance [20]. Most studies to
date have been performed with in vitro or in vivo labora-
tory derived strains and the relevance of these findings to
clinical infection in humans is unclear. A major limitation
of previous studies assessing transcriptional changes in
hVISA/VISA strains is that only single pairs of isolates have
been used. This has made it difficult to draw conclusions
about the relevance of the transcriptional differences in
VISA strains as often hundreds of genes were differentially
regulated [15,17,21].
We recently characterized five clinical pairs of VSSA and
hVISA/VISA, isolated from patients with persistent MRSA
bacteremia, and in whom vancomycin treatment failed
[12]. These isolates demonstrated phenotypic changes
commonly associated with VISA strains, including cell
wall thickening and reduced autolytic activity. The level of
resistance demonstrated in these strains is more fre-
quently found clinically, as strains with a vancomycin
MIC of ≥ 8 mg/L are still uncommon. In addition, we have
obtained three pairs of clinical isolates from patients with
persistent MRSA bacteremia and vancomycin treatment
failure, in whom low-level vancomycin resistance did not
develop. We used microarray analysis to investigate the
transcriptional differences in the five VSSA and hVISA/
VISA pairs and the three control pairs to determine if con-
sistent transcriptional changes occur in clinical MRSA iso-
lates associated with persistent bacteraemia and a
common level of vancomycin resistance (hVISA/VISA
with vancomycin MICs of 2–4 mg/L). Because many
patients infected with hVISA/VISA strains have persistent
infection, and because of the significant changes in sur-
face structure of these hVISA/VISA strains, the impact of
the VISA/VISA phenotype on host-pathogen interactions
was also assessed.
Here we demonstrate that transcriptome patterns are
divergent in different isolates pairs, and up-regulation of
the "cell wall stimulon" and mutations in vraSR are not
essential for the expression of vancomycin resistance in
hVISA/VISA isolates. In addition we demonstrate for the
first time that the hVISA/VISA phenotype is associated
with significant changes in the expression of capsule and
protein A on the cell surface, and hVISA/VISA strains pro-
duce less innate immune system activation.
Results
Isolate characteristics
Five VSSA and hVISA/VISA isolate pairs (pairs 1 to 5) were
included in this study as well as 3 control pairs of strains
(pairs 6 to 8). The reason for including the control pairs
was to determine if transcriptional changes are found in
MRSA isolates after persistent bacteraemia, but where
hVISA/VISA does not develop. If similar transcriptionalPage 2 of 14
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and hVISA/VISA pairs it would suggest these changes were
independent of the resistance mechanism. In the three
control pairs (pairs 6 to 8) pulsed field gel electrophoresis
(PFGE) demonstrated identical banding patterns for iso-
late pairs, and identical spa types (JKD6084 and JKD6089,
spa type 382; JKD6090 and JKD6094, spa type 382;
JKD6095 and JKD6097, spa type 3). All 6 control isolates
were fully vancomycin susceptible by population analysis
profile testing, and had vancomycin MICs within the sus-
ceptible range (Table 1).
Microarray analysis of control pairs
No genes were differentially expressed in pairs 7 and 8
when the later clinical isolate (JKD6094 and JKD6097)
were compared to the earlier isolate (JKD6090 and
JKD6095). For isolate pair 6 only two genes were differen-
tially expressed; SACOL0935 (D-alanine-activating
enzyme/D-alanine-D-alanyl carrier protein ligase), fold
ratio 2.32; and SACOL0936 (DltB, a putative activated D-
alanine membrane transport protein), fold ratio 2.27.
Microarray analysis of clinical hVISA/VISA strains
For the VSSA and hVISA/VISA pairs a list of genes of inter-
est was generated as described in the methods section.
These results are presented as the fold ratio of hVISA/VISA
compared to the related VSSA isolate. There were 54 genes
that were down-regulated, and 89 genes that were up-reg-
ulated in at least two isolate pairs. Selected genes from this
list which were of particular interest are highlighted in fig-
ure 1 and additional file 1. The complete gene list is also
provided in additional file 2. Down-regulation of the quo-
rum sensing global regulator agr (agrA, agrB) was promi-
nent across three pairs. This would be expected to have
secondary effects on exotoxin production and expression
of cell adhesion molecules, and a number of genes
involved in pathogenesis and toxin production, and cell
surface adhesion molecules were indeed significantly
down-regulated (spa, fnbA, fnbB, efb, putative exotoxin
SACOL0478, fibrinogen-binding protein related proteins
and precursors SACOL1164 and SACOL1169). Of partic-
ular note, marked down-regulation of the spa gene
SACOL0095 was demonstrated in four of the five hVISA/
VISA isolates, and another IgG-binding protein,
SACOL2418 was down-regulated in all five isolates.
Table 1: Study isolates and susceptibility results
Isolate Phenotypea MICb(μg/ml) Reference or Comment
VCM TEIC
Pair 1
JKD 6000 VSSA 2.0 0.5 [12]
JKD 6001 VISA 4.0 8.0 [12]
Pair 2
JKD 6009 VSSA 1.0 0.5 [12]
JKD 6008 VISA 4.0 2.0 [12]
Pair 3
JKD 6021 VSSA 1.0 0.25 [12]
JKD 6023 VISA 4.0 8.0 [12]
Pair 4
JKD 6052 VSSA 1.0 0.5 [12]
JKD 6051 hVISA 2.0 4.0 [12]
Pair 5
JKD 6004 VSSA 1.0 0.5 [12]
JKD 6005 hVISA 2.0 4.0 [12]
Pair 6 (control)
JKD 6084 VSSA 0.5 ≤ 0.25 [this study]
JKD 6089 VSSA 1.0 ≤ 0.25 [this study]
Pair 7 (control)
JKD 6090 VSSA 0.5 ≤ 0.25 [this study]
JKD 6094 VSSA 0.5 ≤ 0.25 [this study]
Pair 8 (control)
JKD 6095 VSSA 1.0 0.5 [this study]
JKD 6097 VSSA 1.0 0.5 [this study]
Other Isolates
P1 Cap8 positive [57]
Newman Cap5 positive [57]
aVSSA, vancomycin-susceptible S. aureus; VISA, vancomycin-intermediate S. aureus; hVISA, hetero-VISA.
bMinimum inhibitory concentration. VCM, vancomycin; TEIC, teicoplanin.Page 3 of 14
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included genes involved in urease production and nitro-
gen metabolism (ureA, ureB, ureC, ureD, ureE, ureF, ureG,
narG, narH, nirD) and amino acid biosynthesis for aspar-
tate (hom, lysC, asd, dapA, dapB, dapD). In addition
genes encoding pyruvate biosynthesis were also up-regu-
lated (ilvB, ilvC, ilvE, leuA). Of particular interest was the
up-regulation of capsular polysaccharide biosynthesis
genes (cap5A, cap5B, cap5D, cap5E, cap5F) in a number
of hVISA/VISA isolates. The gene encoding the SceD pro-
tein (SACOL2088, a putative transglycosylase) was fre-
quently up-regulated. Regulators other than agr, which
had differential expression, included the merR family reg-
ulators SACOL2193 and SACOL2517 in 4 and 3 pairs
respectively, the GntR family regulator (SACOL1997) in 2
pairs, and up-regulation of a putative regulatory gene
(SACOL2585) in 2 pairs, but down-regulation in another
pair.
Previous studies have demonstrated significant transcrip-
tional changes in S. aureus isolates when compared to
non-exposed isolates, after exposure to vancomycin. We
therefore exposed both the susceptible and hVISA/VISA
isolate in pairs 1 to 5 to vancomycin for 30 min prior to
RNA extraction and microarray analysis, in an effort to
detect differences in responses to vancomycin exposure in
hVISA/VISA and VSSA isolates from the same pair. After
exposure of the VSSA and hVISA/VISA in each pair to van-
comycin there was a more pronounced gene down-regula-
tion compared to the initial analysis (Figure 1, and
additional file 2). This included significant down-regula-
tion across 3 of the 5 pairs in the 2-component system
saeSR, and marked down-regulation of MW2407 encod-
ing a hypothetical protein in multiple pairs, suggesting
that vancomycin led to differential effects in gene regula-
tion between the hVISA/VISA isolate and VSSA in each
pair. There were however, no consistent effects of the van-
comycin exposure across all isolate pairs.
A heat map analysis was also performed to assess global
changes in all VSSA and hVISA/VISA isolate pairs, using
the complete microarray data sets. The heat map of all
microarray data (additional file 3) demonstrates that
although there are some consistent changes across a few of
the isolate pairs (in a small subset of genes, such as genes
encoding capsule production, protein A, and urease pro-
duction), there are significant differences in the global
transcriptional patterns in different hVISA/VISA isolates,
such that the global transcriptional patterns were diver-
gent between different isolate pairs.
Genes associated with the "cell wall stress stimulon" are 
not consistently up-regulated in hVISA/VISA
Because of the recent interest in the importance of up-reg-
ulation of the "cell wall stimulon" in hVISA/VISA, linked
with cell wall thickening and resistance, we specifically
analyzed the transcriptional changes in these genes. Two
isolates pairs demonstrated up-regulation of vraS and
associated genes in the initial microarray analysis, but of
particular interest was the lack of any significant change in
two pairs (pair 1 and 5), and the down regulation in the
another pair (pair 3) (Figure 2). After vancomycin expo-
sure a number of these cell wall genes were also down reg-
Heat map analysis of selected genesFigure 1
Heat map analysis of selected genes. Heat map analysis of selected genes which were differentially expressed in at least 2 
isolate pairs. The results are expressed as fold ratio of gene expression for hVISA/VISA compared to VSSA. Results are pre-
sented for all 5 isolate pairs without antibiotic exposure and all 5 isolate pairs after exposure to vancomycin. This figure shows 
the upper quartile of these selected genes, for the full image please see additional file 1.Page 4 of 14
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SACOL2116, SACOL2571).
Protein expression and capsule production correlate with 
array results
To determine if the transcriptional changes that were
detected in hVISA/VISA isolates resulted in changes in
protein A and capsule production, as well as urease activ-
ity, expression was determined for all isolates. A signifi-
cant decrease in protein A production was demonstrated
for 4 of the 5 pairs (Figure 3). For the 5th pair, protein A
production was low in both isolates. Urease activity was
higher for the hVISA/VISA isolates compared to the VSSA
isolates for 4 of the 5 pairs (Table 2). These results corre-
lated well with spa and ureA gene expression (Table 2, Fig-
ure 3, additional file 2). A PCR was designed to determine
the capsule genotype of isolates (capsule type 5 or capsule
type 8). All isolates from pairs 1 to 5 were capsule type 8
strains by PCR. Capsule immunoblot confirmed the PCR
capsule typing results, and demonstrated a significant
increase in capsule expression in 4 of the 5 pairs (Figure
4). The last pair (no 5) had minimal capsule expression in
the VSSA or hVISA strain, and these results also correlated
well with microarray data.
Sequencing of regulatory genes does not demonstrate 
mutations leading to altered regulatory gene expression
In an effort to identify any genetic mutations leading to
the resistant phenotype in the 5 hVISA/VISA strains, regu-
latory loci which were differentially expressed in the
microarray experiments or which were predicted to be
linked to the microarray results were sequenced in all 5
VSSA and hVISA/VISA pairs. We found no sequence
changes between the VSSA and hVISA/VISA in each pair in
the two-component regulators saeSR and vraSR, nor in the
genes encoding the merR-like regulators SACOL2193 and
SACOL2517. The regulatory genes mgrA (SA0641) and rot
(repressor of toxins) were also sequenced. Although mgrA
was not differentially expressed on the microarray results,
it has recently been shown to be an important global reg-
ulator in S. aureus, with effects on autolytic activity, pro-
tein A expression and capsule production [22]. rot is a sarA
homologue which is blocked by RNAIII [23,24]. It has
effects on expression of multiple genes, including those
involved in synthesis of urease, protein A, and ABC trans-
porters [25]. Again, no mutations were found in either
gene. Finally, because of the dramatic decrease in
MW2407 expression in the vancomycin exposure experi-
ments, the region MW2406 to MW2408 was sequenced
(this gene on the TIGR version S. aureus array is unique to
MW2). The expected product size based on the MW2
genome was 2898 bp, but the amplified fragment from
our strains was ~1900 bp. There were no differences in the
Heat map analysis of cell wall genesFigure 2
Heat map analysis of cell wall genes. Heat map analysis of "core cell wall genes" and additional cell wall genes which have 
been commonly shown to be important in cell wall biosynthesis [56]. The results are expressed as fold ratio of gene expression 
for hVISA/VISA compared to VSSA. Results are presented for all 5 isolate pairs without antibiotic exposure and all 5 isolate 
pairs after exposure to vancomycin.Page 5 of 14
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region amplified in our strains matched closely to 2
regions in MRSACOL encoding tandem lipoproteins and
a hypothetical protein (SACOL2496, SACOL2498 and
SACOL2492, SACOL2493).
Increasing vancomycin resistance is associated with 
reduced NF-κB activation and reduced pro-inflammatory 
cytokine release
Because we detected a number of significant changes in
staphylococcal surface structures that interact with the
innate immune system during the evolution of hVISA/
VISA, we next wished to establish if hVISA/VISA displayed
a decreased activation of the prototypic inflammatory
transcription factor NF-κB. As shown in Figure 5, there
was a statistically significant decrease in NF-κB activation
demonstrated with 4 of the 5 hVISA/VISA isolates com-
pared to their parent VSSA strain, particularly at lower
concentrations. This appeared to correlate with the vanco-
mycin MIC result, with reduced NF-κB activation detected
with all the strains with a vancomycin MIC of 4 mg/L, but
only with one of those with an MIC of 2 mg/L. To deter-
mine the biological impact of this effect, a single pair
(JKD6021 and JKD6023) were selected to determine if the
reduced NF-κB activation resulted in a diminished expres-
Capsule immunoblot comparison of VSSA to hVISA/VISAFigure 4
Capsule immunoblot comparison of VSSA to hVISA/
VISA. Capsule immuoblot using anti-capsule type 8 anti-
body. Serial 3-fold dilutions of crude capsule extracts were 
loaded onto nitrocellulose membrane. Positive control, cap-
sule type 8 positive strain P1; negative control, capsule type 5 
positive strain Newman.
Western blot analysis of protein A productionFigure 3
Western blot analysis of protein A production. Analy-
sis of protein A production by Western Blot in hVISA/VISA 
and VSSA pairs. A. Pair 1 (lane 1, JKD 6000; lane 2, JKD 
6001), pair 2 (lane 3, JKD 6009; lane 4, JKD 6008), pair 3 
(lane 5, JKD 6021; lane 6, JKD 6023), pair 4 (lane 7, JKD 
6052, lane 8, JKD 6051), pair 5 (lane 9, JKD 6004; lane 10, 
JKD 6005). B. Fold ratios for protein A production and pro-





B      
 
       VISA/VSSA fold ratio (pair no.) 
 
            1      2  3       4  5 
  
Western blot        0.07   0.10           0.27     0.05        0.94 
          
Microarray        0.12   0.08          0.19     0.11        0.98 
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TNF-α and IL-1β. As demonstrated in Figure 6, after 6
hours exposure to both strains, there was a significant
decrease in TNF-α expression when comparing JKD6021
to JKD6023 (p < 0.001), while IL-1β expression was sub-
stantially decreased.
Discussion
Methicillin-resistant Staphylococcus aureus (MRSA) is on
the rise globally [26,27], with recent failures of vancomy-
cin therapy for MRSA infections associated with low-level
resistance to glycopeptides [3,28]. In addition, persistent
MRSA bacteremia despite vancomycin therapy has also
been recognized as an important clinical syndrome which
is incompletely understood [29]. We have investigated
transcriptional changes in five clinical pairs of VSSA and
hVISA/VISA isolated from patients with persistent MRSA
bacteremia on vancomycin therapy. Multiple gene expres-
sion changes were found in the hVISA/VISA strains com-
pared to the parent VSSA, but essentially no changes were
found in three control pairs of strains, suggesting the tran-
scriptional changes in the hVISA/VISA strains are linked to
resistance. Despite the different PFGE patterns [12], the
five isolate pairs are closely related as determined by
sequence based typing (by multi-locus sequence typing all
are ST239-MRSA) [data not shown] and 4 of the 5 isolate
pairs have identical spa types [12]). Although there were
some consistent transcriptional changes found, there were
very few consistent changes across all pairs, suggesting
that multiple transcriptional pathways lead to low-level
NF-κB activation results for VSSA and hVISA/VISA isolate pairsFigure 5
NF-κB activation results for VSSA and hVISA/VISA 
isolate pairs. Stably transfected RAW cells with an ELAM-
NF-kB reporter construct were exposed to formaldehyde 
killed VSSA and hVISA/VISA pairs for 6 hours. Results are 
presented as fold NF-κB activation for hVISA/VISA compared 
to VSSA and are the result of multiple replicates. (* p < 0.05)
Table 2: Urease assay results and comparison to microarray 
results
VISA/VSSA fold ratio
Strain Urease activity (μmol 







JKD 6001 8.2 >8.2 3.75*
Pair 2
JKD 6009 3.9
JKD 6008 6.8 1.7 1.40
Pair 3
JKD 6021 3.7
JKD 6023 17.1 4.6 1.82*
Pair 4
JKD 6052 3.8
JKD 6051 5.17 1.5 2.69*
Pair 5
JKD 6004 2.3
JKD 6005 1.5 0.65 0.73
Abbreviations: VSSA, vancomycin-susceptible S. aureus; VISA, 
vancomycin intermediate S. aureus.
*Microarray fold ratios were statistically significant.Page 7 of 14
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ported by the detailed analysis of "cell wall stimulon" acti-
vation in our strains. These results are most clearly
demonstrated by the global heat map analysis (additional
file 3) that displays the major differences in the transcrip-
tional patterns among the isolate pairs. In addition, we
have demonstrated for the first time that the development
of low-level vancomycin resistance in patients with per-
sistent bacteraemia is associated with changes in the cell
surface and alterations in the host immune response.
These are important findings demonstrating that S. aureus
strains evolve to alter immune system activation, in asso-
ciation with changes leading to reduced response to van-
comycin therapy.
A consistent theme from other studies of VISA strains has
been the up-regulation of cell wall biosynthetic genes
[14,15,18,21], including the vraSR two-component regu-
latory system and genes from this regulon. It is hypothe-
sized that vancomycin activates the "cell wall stress
stimulon" which then remains activated in VISA strains
even after the vancomycin is removed. However, by exam-
ining multiple clinical isolates, we have established that
low-level vancomycin resistance can be acquired in S.
aureus without up-regulation of vraSR and other genes of
the "cell wall stimulon". In fact, these genes were down-
regulated in one VISA strain (JKD6023) in the initial anal-
ysis and in another strain (JKD6005) after vancomycin
exposure. This is an important finding that clearly demon-
strates that the hVISA/VISA phenotype can develop in
clinical S. aureus isolates (associated with cell wall thick-
ening and reduced autolytic activity [12]) without a sus-
tained induction of the "cell wall stimulon". In addition,
despite recent data suggesting that mutations in the vraSR
operon are common in VISA strains [6], we found no
mutations in this region in our strains. It is important to
note that our hVISA/VISA isolates are all the same MLST
type, and therefore are not from significantly different
genetic backgrounds. This suggests that different pathways
to resistance exist, even in genetically closely related
strains, but that our results may not however apply to
strains of other genetic backgrounds, such as Mu50 and
Mu3.
Recent studies have highlighted some of the difficulties in
interpreting microarray data without analysis of the effects
the transcriptional changes on the expression of gene
products [30]. We addressed this issue by quantitating a
number of the gene products which were differentially
expressed in the hVISA/VISA isolates. The microarray data
was supported by protein A production, capsule expres-
sion and urease activity analysis. In addition, our previous
real-time PCR analysis of RNAIII expression correlates
well with the decreased agr expression found in the micro-
array analysis [12]. The increased capsule expression and
reduced protein A production demonstrated in 4 of the 5
hVISA/VISA strains is of interest. These changes are likely
to have significant implications for host pathogen interac-
tions, and in fact, could favor persistent infection. For this
reason, we performed experiments to determine the
impact of the hVISA/VISA phenotype on immune system
activation, as measured by NF-κB activation.
We have clearly demonstrated that the development of
VISA is associated with changes in NF-κB activation,
which will affect the host pro-inflammatory response to
infection. This was clearly demonstrated with the 3 VISA
strains that had a vancomycin MIC of 4 mg/L, and one of
the strains with a vancomycin MIC of 2 mg/L (Figure 5).
Although hVISA/VISA strains may have slower growth
rates compared to VSSA, we controlled for this in our NF-
κB activation assays by growing cells to stationary phase
and performing colony counts so that equivalent inocu-
lums of killed cells were used in the assays. Many different
staphylococcal components activate the innate immune
system and induce NF-κB activation; including protein A,
teichoic acids and peptidoglycan [31]. The activation of
NF-κB in turn up-regulates the expression of pro-inflam-
matory cytokines including TNF-α and IL-1β. The biolog-
ical impact of this altered immune response was further
highlighted by using the strain pair JKD6021 and
JKD6023 which confirmed that RAW cells exposed to
VISA strains compared to VSSA isolates display a reduced
TNF-α and IL-1β expression. Secreted exotoxins also acti-
vate innate immune responses, and although we did not
measure these directly, the down-regulation of agr in
hVISA/VISA strains, including our strains, would also
limit immune activation by reducing exotoxin produc-
tion. The cell surface changes we demonstrated in our
TNF-α and IL-1β expressionFigure 6
TNF-α and IL-1β expression. TNF-α and IL-1β expres-
sion from RAW264.7 cells after 6 hours exposure to formal-
dehyde killed JKD6021 (VSSA) and JKD6023 (VISA). (** p < 
0.001).Page 8 of 14
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host responses demonstrated here.
Our results confirm the potential importance of changes
in the agr two-component regulatory system in hVISA/
VISA strains [32,33]. Recently, reduced agr function has
been demonstrated in isolates from patients with persist-
ent MRSA bacteraemia where vancomycin resistance was
not demonstrated [29,34]. Although we have demon-
strated reduced agr expression in a number of our strains
previously by real time PCR [12] and now by microarray
analysis, we did not find any changes in agr expression in
isolates from patients with persistent bacteremia without
hVISA/VISA. This suggests that there is a link between
reduced agr expression and low-level vancomycin resist-
ance, but that reduced agr expression is not always associ-
ated with prolonged MRSA bacteraemia and vancomycin
therapy as previously suggested [29,34].
Although up-regulation of capsule genes has been demon-
strated in other VISA strains [15,20] enhanced capsule
production has never previously been confirmed. Loss of
capsule typability has been reported in VISA revertant
strains obtained by serial passage [35], and electron
microscopy of VISA strain JH9 demonstrates what is prob-
ably excess capsule [11], however the potential impor-
tance of capsule expression in the hVISA/VISA phenotype
has not been considered. Over-expression of staphylococ-
cal capsular polysaccharide type 8 has been shown to pro-
tect against in vitro opsonophagocytic killing by human
neutrophils and lead to more persistent blood stream and
organ infection in mice [36]. Recently, up-regulation of
capsule gene expression has been documented as part of
the global transcriptional response that contributes to
innate immune system evasion [37]. It is conceivable that
the changes in capsule expression are an adaptation to
allow the bacteria to persist in the blood stream and evade
immune system killing. It has also been shown that S.
aureus with increased capsule are less adherent to epithe-
lial cell monolayers, and to damaged heart valves [38],
and recently is has been determined that increased cap-
sule expression blocks clumping factor A-mediated bind-
ing of staphylococci to fibrinogen and platelets [39].
Therefore the increased capsule changes we observed may
play a role in the reduced biofilm formation that we have
previously demonstrated in these same strains [12], possi-
bly by masking important adhesins involved in the early
stages of biofilm formation. It is also worth considering if
the increased capsule production could directly contrib-
ute to the low-level vancomycin resistance in some hVISA/
VISA strains, or interfere with the agr quorum sensing sys-
tem, and explain the quorum sensing changes observed in
these hVISA/VISA strains (reduced agr expression), espe-
cially as mutations in the agr operon were not found in
the strains [12]. More work is needed to determine if
increased capsule expression is common in many hVISA/
VISA strains, and to understand the impact of capsule pro-
duction on the expression of low-level vancomycin resist-
ance in S. aureus, and on the agr system.
Down-regulation of spa is one of the most consistent tran-
scriptional changes found in hVISA/VISA strains
[14,15,17,33,40]. We have shown by western blot that
reduced spa expression leads to almost complete absence
of protein A expression in hVISA/VISA strains. In addi-
tion, consistent down-regulation of the gene encoding
another IgG-binding protein (Sbi) was also found. These
changes are likely to have significant biological implica-
tions, and could partly explain the changes in NF-κB acti-
vation. Protein A is a major surface protein of S. aureus. It
binds to the Fc region of IgG, and the Fab portion of Ig
belonging to the VH3+ gene family [41] where it may act
as a B cell superantigen, but also binds to several other
proteins including gC1qR which is expressed on activated
platelets [41]. Protein A triggers platelet aggregation [42],
and along with other staphylococcal surface proteins
(such as fibronectin binding proteins [FnBPs]) has been
shown to activate platelets [43,44]. Upon activation plate-
lets release platelet microbiocidal proteins (PMPs) [45].
The interaction between S. aureus and platelets, and in
particular the role of PMPs in protection against intravas-
cular infections, and the link between hVISA/VISA and
reduced susceptibility to PMP has been well described
[29,32]. The decreased protein A and FnBPs expression
seen in our hVISA/VISA strains would be expected to lead
to less platelet activation. Recently, protein A has also
been shown to activate a respiratory epithelial inflamma-
tory response by binding to TNR-α receptor 1 [46]. Sta-
phylococcal protein Sbi is an IgG- and β2 glycoprotein I-
binding protein that has been found to be up-regulated
after exposure to human serum [47]. Decreases in spa
expression were not seen in the 3 control pairs of strains.
Nonetheless, along with increased capsule expression the
spa changes have the potential to alter immune system
response to infection and promote persistent infection.
Increased urease activity has not been reported in hVISA/
VISA strains. Urease is involved in the urea cycle and
amino acid metabolism as well as purine metabolism
[48]. The reasons for the increased production of urease in
our hVISA/VISA strains is not clear, but may be linked to
increased amino acid biosynthesis, with increased expres-
sion of genes involved in aspartate biosynthesis in partic-
ular found in the microarray analysis. Recently, up-
regulation of urease production has been demonstrated in
S. aureus biofilms, and it was hypothesized that increased
ammonium and/or ammonia is required to counteract
the acid environment in the biofilm. It is not clear how
this may be linked to the hVISA/VISA phenotype, except
that increased energy requirements and increased metab-Page 9 of 14
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activity.
Sequencing of a number of regulatory genes that were dif-
ferentially expressed in the microarray analysis (vraSR,
saeSR, SACOL2193, SACOL2517) or were potentially
involved in the changes we found (mrgA and rot) revealed
no nucleotide changes. However, any mutations associ-
ated with resistance in these strains are clearly leading to
global transcriptional changes in hVISA/VISA isolates. The
recent work by Mwangi et al [6] demonstrated that a small
number of mutations could lead to an increase in vanco-
mycin MIC up to 4 mg/L in the strain they studied. In our
previous study of these VSSA and hVISA/VISA clinical iso-
lates we demonstrated by PFGE a difference in banding
patterns for the pairs JKD6000/JKD6001 and JKD6021/
JKD6023 [12]. A genomic microarray comparison using
the whole genome of MRSACOL and selected unique
genes from S. aureus strains Mu50, MW2 and N315 (TIGR
version 2 array) failed to reveal any genetic changes in
these pairs [12]. Because the aims of this study were to
determine transcriptional changes using the TIGR ver2
arrays, we have not been able to provide any further expla-
nation for the difference in PFGE banding patterns. It is
possible that loss of phage DNA could explain the
changes, and is unlikely to contribute to the resistance
phenotype, but confirmation would require a whole
genome comparison.
Conclusion
The emergence of hVISA/VISA from vancomycin-suscepti-
ble S. aureus can occur by different transcriptional path-
ways, even in closely related strains, and it appears that
up-regulation of the "cell wall stimulon" and mutations
in vraSR are not essential for the generation of hVISA/
VISA. Changes in capsule production and protein A
expression frequently accompany the altered antibiotic
susceptibility in hVISA/VISA strains, and reduced innate
immune activation may be another factor promoting per-
sistence of infection. Further work is required to fully
understand the impact of changes in immune recognition
of hVISA/VISA strains. Identifying the mutation or muta-
tions leading to resistance in our strains will require a glo-
bal comparative genomics approach.
Methods
Bacterial strains, antibiotic susceptibility and molecular 
typing
Staphylococcus aureus strains are listed in table 1. All strains
were clinical isolates from patients with persistent methi-
cillin-resistant S. aureus bacteraemia (blood culture posi-
tive after > 7 days of vancomycin therapy) [12]. Isolate
pairs 1 to 5 have been previously well characterized and
represent VSSA and hVISA/VISA pairs [12]. Isolate pairs 6
to 8 are blood culture isolates (patients with bacteremia
for 8–22 days) where hVISA/VISA was not detected in the
later clinical isolate. All isolates were grown in brain heart
infusion broth (BHIB) (Oxoid). For the control pairs van-
comycin population analysis profile (PAP), vancomycin
and teicoplanin broth minimum inhibitory concentra-
tions (MIC), PFGE and spa typing were performed as pre-
viously described [12].
Preparation of total RNA
After overnight growth in BHIB a 1 in 100 dilution was
made in 50 ml of BHIB and incubated at 37°C with shak-
ing. Exponential-phase culture (20 ml) was added to 10
ml of an RNA stabilization reagent (RNA later, Qiagen)
and allowed to stand for 10 min after mixing. Total RNA
was prepared using the RNeasy Midi Kit (Qiagen) [12].
For vancomycin experiments, vancomycin (Sigma) was
added to cultures in early exponential growth (final con-
centration 0.5 × MIC) for 30 min before RNA extraction.
Preparation of Cy3- and Cy5-dUTP labeled cDNA probe
Transcription profiling to compare the later clinical iso-
late (VISA/hVISA for pairs 1 to 5, VSSA for pairs 6 to 8) to
the related initial clinical isolate (VSSA) was performed
for each pair without antibiotics, and repeated after expo-
sure of both the VSSA and hVISA/VISA isolates to vanco-
mycin for pairs 1 to 5. cDNA was synthesized using
SuperScript™ II RNase H-Reverse Transcriptase (Invitro-
gen) incorporating aminoallyl-dUTP at 42°C with the fol-
lowing reaction mixture (RNA 5 μg, random hexamers 6
μg, Superscript II RT 400 U, 0.5 mM dATP, dCTP, dGTP,
0.2 mM dTTP, 0.3 mM aa-dUTP [Amersham Biosciences];
total volume 30.7 μl). The RNA was hydrolyzed by addi-
tion of 10 μl 0.5 M EDTA and 10 μl 1 M NaOH with incu-
bation at 65°C for 15 min, followed by addition of 25 μl
1 M Tris (pH 7.0) to neutralize the pH. The cDNA was col-
lected using a QIAquick column (Qiagen) and dried to
completion in a vacuum concentrator. The aminoallyl-
labeled cDNA was resuspended in 4.5 μl 0.1 M sodium
bicarbonate buffer (pH 9.3) and incubated at room tem-
perature for 2 hours after addition of Cy3 or Cy5 (Amer-
sham Biosciences) resuspended in 4.5 μl DMSO (Sigma).
The probe was purified using a microcon-30 column. The
quantity of cDNA and incorporation ratio of Cy dye was
measured by spectrophotometry (NanoDrop ND-1000,
NanoDrop Technologies, DE, USA) to confirm acceptable
results and then the two differentially labeled probes were
mixed and dried to completion in a vacuum concentrator.
Array hybridization and analysis
Array hybridization, washing and scanning using version
2 Staphylococcus aureus microarray slides (The Institute for
Genomic Research, MD, USA) was performed as described
previously [12]. Briefly, 30 μl of hybridization mixture
containing Cy3- and Cy5-dUTP labeled probe, 15 μl for-
mamide (Sigma), 5 × SSC, 0.1% SDS, and 22.5 μg herringPage 10 of 14
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applied to the microarray slide and incubated overnight at
42°C. The microarray was washed sequentially in 2 × SSC,
0.1% SDS; 0.1 × SSC, 0.1% SDS; and 0.1 × SSC and then
dried. The microarrays were scanned with the GMS418
Array scanner (Genetic MicroSystems) to measure the flu-
orescence of the Cy3 and Cy5 labeled cDNA hybridized to
the microarray. The images were combined and quantifi-
cation of fluorescent and background intensity deter-
mined using ImaGene™ ver 5.1 (Biodiscovery).
RNA extraction and hybridizations were performed in
triplicate, and the dye swapped with each replicate. Using
BASE [49] the data from the three biological replicates
were combined and analyzed using Bioconductor and in
particular Limma [50]. After global lowess normalization
the log-ratios for each array were scaled so that the median
absolute deviation was the same between arrays. For each
gene ID a fold ratio of later clinical isolate (hVISA/VISA
for pairs 1 to 5) compared to the earlier clinical isolate
(VSSA) was calculated. Using a moderated t-test P-values
were calculated and adjusted for multiple testing using
false-discovery-rate (FDR). A ≥ 1.5-fold change and P
value < 0.05 was considered significant. For the hVISA/
VISA comparison any genes which were consistently up or
down regulated across at least two clinical pairs was
included in the set of "genes of interest". Heat maps of the
normalized microarray results were generated using MeV
[51].
Protein Extraction
Cell wall associated proteins for protein A quantification
were extracted as previously described [52]. Isolates were
grown in BHIB in an identical manner as described for
RNA extractions. Thirty ml of exponential stage culture
was placed in a falcon tube and centrifuged at 5000 × g for
10 min. After removal of the supernatant 600 μl of extrac-
tion buffer (30% raffinose in 0.05 M Tris [pH 7.5] with
0.145 M NaCl) containing lysostaphin (Sigma) (250 ug),
10 μg of DNase (Sigma), 1 mg ml-1 iodoacetamide
(Sigma), and 1 mM ml-1 phenylmethylsulfonyl fluoride
(Sigma) was added. The mixture was incubated for 1 h at
37°C with rotation and then centrifuged at 8000 × g for
10 min, and the supernatant was centrifuged at 8000 × g
for a further 10 min. Cellular protein for assessment of
urease activity was extracted from eight ml of culture. The
culture was pelleted, washed in PBS at 4°C, and resus-
pended in 1 ml PBS (4°C). The cells were disrupted in a
FastPrep™ FP120 (Bio101 Savant, CA, USA) (setting 6 for
45 sec × 2) and the tube was centrifuged at 12,000 × g for
30 min at 4°C. The supernatant was transferred to a new
tube. Protein concentrations were measured using the
BCA protein assay kit (Pierce, IL, USA) and stored in aliq-
uots at -80°C.
SDS-PAGE and western blot analysis for protein A 
expression
Fifteen μg of cell wall associated protein from each isolate
was separated in a 12% (wt vol-1) SDS-PAGE gel. The pro-
tein samples were transferred from the SDS-PAGE gel to
cellulose nitrate transfer membrane (Schleicher &
Schuell). A mouse derived monoclonal anti-protein A
antibody (2000 × dilution) (Sigma), and secondary sheep
anti-mouse IgG peroxidase conjugate (2000 × dilution)
(Silenus) were used. The blots were developed using the
Western Lightening chemiluminescence kit (Perkin-
Elmer) and the image acquired and analyzed using the
LAS-3000 Luminescent Image Analysis System (Fujifilm,
Tokyo, Japan) and Multi Gauge version 2.2 software (Fuji-
film, Tokyo, Japan).
Urease Assays
Urease activity was measured using a coupled enzyme
assay [53]. The 1.5 ml reaction mixture contained 31 mM
Tris-HCl (pH 8.0), 10 mM urea (Amresco, OH, USA), 810
μM 2-oxoglutarate (Sigma), 240 μM NADH and 1.34 mg
glutamate dehydrogenase (Sigma). Reactions were per-
formed at room temperature and NADH degradation was
measured by absorbance at 340 nM using a 552 UV-VIS
spectrophotometer (Perkin-Elmer). The urease activity of
each isolate was expressed as μmol of urea hydrolyzed
min-1 mg of protein-1.
Capsule typing and Quantification
A multiplex PCR for capsule genotyping (CP5 and CP8)
was designed using sequences available in NCBI (acces-
sion numbers for cap5, U811973; cap8, U73374). The
forward primer was in Cap5/8G and the reverse primers in
the variable regions, Cap5H and Cap8H (Table 3). The
CP8 positive strain P1 and the CP5 positive strain New-
man were used as controls. For capsule quantification a
capsule immunoblot was performed [36]. Crude capsule
extracts were prepared after growth in BHIB for 18 h at
37°C, using a previously described method [54]. After
adjusting the OD600 to 0.5, 10 ml of culture was pelleted,
resuspended in 500 μl PBS, then treated with the follow-
ing enzymes consecutively at 37°C; lysostaphin (sigma)
200 μg ml-1 for 15 min; DNase I (sigma) 300 U ml-1 for 15
min; and proteinase K (sigma) 100 μg ml-1 for 1 h, and
then inactivated at 75°C for 10 min. Serial dilutions were
loaded onto nitrocellulose membrane using a dot-blot
apparatus. After blocking with 5% skim milk the mem-
brane was incubated with CP8-specific rabbit antiserum
kindly provided by Jean Lee, and then sheep anti-rabbit
IgG peroxidase conjugate (Chemicon, Australia). The
blots were developed as described above.
DNA techniques
Genomic DNA was extracted using the GenElute Bacterial
Genomic DNA Kit (Sigma). PCR was carried out using TaqPage 11 of 14
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sequencing was performed using the BigDye Terminator
version 3.1 cycle sequencing kits (Applied Biosystems)
and the reaction mixtures were analyzed with the 3730
DNA Analyser (Applied Biosystems). Primers for amplify-
ing and sequencing vraSR, saeSR, rot, SACOL2193 and
SACOL2517, MW2406 to MW2407, and mgrA (SA0641)
were designed using the MRSA COL, MW2 and N315
genome sequences (Table 3).
NF-κB assay
Staphylococcus aureus cells were prepared from stationary
phase cultures by washing in cold PBS and resuspending
in 5% formaldehyde for 1 h, followed by additional
washes in PBS. Colony counts were performed prior to the
addition of formaldehyde, to allow inoculation of equiv-
alent cell numbers in the stimulation assays. Three biolog-
ical replicates were prepared for each isolate. RAW264.7
mouse macrophage cells stably expressing the NF-κB-
dependent ELAM-luciferase reporter construct were used
[55]. Cells were seeded at 2 × 104 cells/well of a 96-well
flat bottomed tissue culture plate in 100 μl LPS-free media
(RPMI plus 0.5 mg/ml G418, supplemented with 10%
FCS and 1 mM L-glutamine) and incubated overnight at
37°C, 5% CO2. Cells were then stimulated with VSSA or
hVISA/VISA isolates in triplicate, at a range of concentra-
tions for 6 h at 37°C, 5% CO2. After removing the media
50 μl of 1 × Promega passive lysis buffer was added to
each well (5 min at room temperature). Twenty μl from
each well was transferred to a white opaque TC96 plate,
and 30 μl Luciferase assay reagent (Promega) added. Luci-
ferase activity was measured with a Fluro-Optima lumi-
nometer. The statistical significance of the data was
evaluated by paired t test using GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA).
TNF-α and IL-1β immunoassays
These assays were performed using the Quantikine Mouse
TNF-α and IL-1β immunoassay kits (R&D Systems)
according to the manufacturers' instructions. Briefly, RAW
264.7 cells were seeded at 2 × 104 cells/well of a 96-well
flat bottomed tissue culture plate in 100 μl LPS-free media
(RPMI supplemented with 10% FCS and 1 mM L-
glutamine) and incubated overnight at 37°C, 5% CO2.
Cells were then stimulated with VSSA and VISA in tripli-
cate for 6 h at 37°C, 5% CO2. After spinning the plates
supernatant from each well was stored at -20°C prior to
analysis. The statistical significance of the data was evalu-
ated by paired t test using GraphPad Prism 4.0 (GraphPad
Software Inc., San Diego, CA)
Authors' contributions
BH carried out all the experimental work, except for the
assay to assess innate immune responses which were per-
formed by DS. The study was conceived by JD, PJ, BH and
AM. PW carried out initial characterization of the strains
used in the study. PJ assisted with statistical analysis and
TS assisted with assessment of sequencing results. AM, JD
and TS assisted BH with drafting the manuscript. All
authors read and approved the final manuscript.
Additional material
Additional file 1
Complete figure 1. Full image of heat map analysis of selected genes 
which were differentially expressed in at least 2 isolate pairs.




Data table 1. Summary of microarray results for the hVISA/VISA to 
VSSA comparison. Any genes which were consistently up or down regu-
lated across at least two clinical pairs were included in the set of "genes of 
interest". Data are presented as the fold ratio of hVISA/VISA to VSSA. 
Table 1a and 1b are without vancomycin exposure. Table 1c and 1d are 
after vancomycin exposure (see methods section for details).
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Table 3: Primers used in study
mgrA F TTG AAG CAC ATG CAG AAA CA
mgrA R TCG CAA CAA ACA CAA CCA TT
mw2406 to 2408 F CCC AAT CTC CTT GAG CTA CAT T
mw2406 to 2408 R TTA GTT GGT TAG GCC AAT AAA AA
saeSR F GGC GGC ATA CAG TTA ATT TCA
saeSR R CAC TCA TTG TTA AAA CAG ATT TCA CTT
vraSR F TTG TCG GTG CTG AAA TCA AT
vraSR R GTT GCG ACG GAT GAG GTT AT
rot F TGT AGA ATT GTTGCA ATT TAA TGG T
rot R TGC CAA CAA CAA AAA GAG GTT
SACOL2193 L CCT TGA CCT ACT TCA GTT TCA TTT
SACOL2193 R ATA AGA AGT ATT CAA ACG AAG ATG ACA
SACOL2517 L GCG CTT TCT TTA CGA GCA CT
SACOL2517 R TGA CGT CGG GTC ATC AAC TA
cap5/8G L TTT TGA AGT TCC CTG GTG TCC
cap8H R TAG CGC CAA GAA TCG CTA TCC
cap5H R ACC AAC AAC CTC ATA TGC TCCPage 12 of 14
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